Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.
With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.
The plan is to bring in-house products to the market as well as through acquisitions.
Lilly's long-acting insulin showed it's more effective in type 1 diabetics than Lantus, but concerns about its overall profile persist.
Bloomberg reports that India's Wockhardt has become an M&A target.
Pfizer will sell two Novartis drugs in the UK.
Sales reps are among the pinked-slipped in Spain.
The FDA has approved Arnuity Ellipta for asthma.
Amgen now hopes a separate study will be enough to support the drug's advancement to a second-line therapy, but the lackluster results may impinge on its EU filing schedule.
GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.
Layoffs are reported to be in the offing.
Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.
Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.
The meningitis and encephalitis medications earned a combined $300 million last year.
AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.
The majority of the layoffs will be in the US.
Patent losses and lost co-promotion agreements put a dent in sales.
The company refutes a Financial Times rumor that one was happening soonish.
Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?
The drug did not hit its Phase III primary target of improving progression-free survival.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.
Executives urge analysts to focus on the company's long-term potential.
CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.
Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
The deal includes a $1.6-billion fee if AbbVie tries to walk away.
AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.
Less-frequent dosing and competitive pricing could spur a shift in market share among products that treat the hereditary blood disorder.
Hepatitis C medication Olysio was a star, but the company cautions competition is coming.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.